에 대한 최신 뉴스 Cabaletta Bio (NASDAQ:CABA) 주식

CABALETTA BIO INC

Cabaletta Bio

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Prescription Drugs

Equities

Markets

CABA

카발레타 바이오(NASDAQ:CABA)의 주가는 수요일 24.38% 상승한 3.01달러에 마감했으며, 전신 경화증(Systemic Sclerosis) 약물 시험 업데이트 이후 시간외 거래에서 4.65% 상승한 주당 3.15달러에 거래되었다.

카발레타 바이오, 전신 경화증 약물 시험 업데이트 이후 수요일 23개월 만에 최대 급등

Cabaletta Bio Inc

Cabana Target Beta ETF

Cabana Target Drawdown 10 ETF

Cabana Target Leading Sector Moderate ETF

Guggenheim analyst John Heinbockel reiterates US Foods Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) with a Buy and maintains $80 price target.

News

Price Target

Reiteration

Analyst Ratings

USFD

Guggenheim Reiterates Buy on US Foods Hldg, Maintains $80 Price Target

<a href="https://www.youtube.com/watch?v=u9kS0t0jkJs" title="https://www.youtube.com/watch?v=u9kS0t0jkJs">https://www.youtube.com/watch?v=u9kS0t0jkJs</a>

Biotech

Macro Economic Events

Global

Economics

General

President Trump Signs Executive Order On Drug Prices; Says European Union Has Been Brutal On Drug Prices; Will No Longer Tolerate Profiteering From Big Pharma; EU Was Most Difficult On Drug Subsidies; Brought Up Weight Loss Drugs With Drug Companies

Barclays analyst Benjamin Theurer maintains Fomento Economico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMX#NYSE">FMX</a>) with a Equal-Weight and raises the price target from $102 to $108.

Fomento Economico Mexicano S.A.B. De C.V.

Barclays Maintains Equal-Weight on Fomento Economico, Raises Price Target to $108

WIIM

GOLD

PAAS

Shares of precious metals stocks are trading lower as gold and silver drop after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

FTRE

FTRE stock has given up its prior gain. Fortrea Holdings shares were trading higher after the company reported better-than-expected Q1 financial results.

B of A Securities analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) with a Neutral and lowers the price target from $47 to $44.

KYMR

B of A Securities Maintains Neutral on Kymera Therapeutics, Lowers Price Target to $44

Barclays analyst Ryan Macwilliams maintains EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) with a Equal-Weight and raises the price target from $9 to $11.

EVCM

Barclays Maintains Equal-Weight on EverCommerce, Raises Price Target to $11

Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Neutral and maintains $47 price target.

SWTX

Guggenheim Reiterates Neutral on SpringWorks Therapeutics, Maintains $47 Price Target

Gold and silver are trading lower after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and raises the price target from $200 to $215.

EPAM

Barclays Maintains Overweight on EPAM Systems, Raises Price Target to $215

<a href="https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.">https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.</a>
&nbsp;
From cutting scan times, to speeding workflow and improving image quality, Philips is already empowering healthcare providers with AI-powered solutions to deliver faster, more accurate diagnoses for their patients [1]. Today at a major industry gathering <a href="https://www.usa.philips.com/healthcare/event/upcoming/ismrm-2025">ISMRM</a>, the company announced a new breakthrough collaboration with NVIDIA to harness cutting-edge advances in AI for MR imaging.
 &nbsp;

NVDA

Reported Earlier: 'Philips Collaborates With NVIDIA To Improve Patient Care In MR With Latest AI Advances' - Phillips

Guggenheim analyst John Heinbockel reiterates Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) with a Buy and maintains $13 price target.

XPOF

Guggenheim Reiterates Buy on Xponential Fitness, Maintains $13 Price Target

SHOP

Shopify shares are trading higher after it was announced the stock will join the Nasdaq-100 beginning May 19.

Hamilton Beach Brands Holdings shares are trading higher after the company raised its quarterly cash dividend.

Barclays analyst Brandt Montour maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Overweight and lowers the price target from $50 to $48.

DKNG

Barclays Maintains Overweight on DraftKings, Lowers Price Target to $48

Politics

President Trump Says China Has Agreed To Stop Fentanyl; Big Incentive For China To Stop; Take China At Their Word

Baird analyst David Koning downgrades TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) from Outperform to Neutral and maintains the price target from $16.5 to $16.5.

Downgrades

TASK

Baird Downgrades TaskUs to Neutral, Maintains Price Target to $16.5

Blade Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) shares are trading higher on Monday after the company reported better-than-<a href="https://www.benzinga.com/pressreleases/25/05/g45343555/blade-air-mobility-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">expected first-quarter 2025 results</a>.
Revenue grew&nbsp;5.4%&nbsp;year-over-year (Y/Y) to&nbsp;$54.3 million, beating the consensus of&nbsp;$49.43 million.
Revenue growth was driven by growth in the Passenger segment. Excluding Canada, which exited in August 2024, revenue increased&nbsp;10.9%&nbsp;Y/Y.
Medical revenue declined 0.2% Y/Y&nbsp;to&nbsp;$35.9&nbsp;million. Short Distance revenue fell&nbsp;5.4%&nbsp;Y/Y to&nbsp;$9.3&nbsp;million, but excluding Canada, it grew&nbsp;28.1% Y/Y.
Jet and Other revenue surged&nbsp;59.9%&nbsp;to&nbsp;$9.1&nbsp;million&nbsp;on increased flight volumes and revenue per flight.
Flight Profit rose&nbsp;18.1% Y/Y&nbsp;to&nbsp;$12.0&nbsp;million, driven by growth in Passenger segments. Flight Margin improved to&nbsp;22.1%&nbsp;from&nbsp;19.7% in the quarter.
Adjusted EBITDA improved by&nbsp;$2.3&nbsp;million&nbsp;Y/Y to&nbsp;$(1.2)&nbsp;million, driven by improvements in the Passenger segment.
Quarterly net loss improved by&nbsp;$0.7&nbsp;million&nbsp;Y/Y to&nbsp;$(3.5)&nbsp;million, mainly due to a&nbsp;$2.3 million&nbsp;improvement in operating losses.
EPS&nbsp;loss of 4 cents exceeded the street <a href="https://www.benzinga.com/earnings">view of loss of 11 cents</a>.
Operating Cash Flow rose by&nbsp;$15.3&nbsp;million&nbsp;to&nbsp;$(0.2)&nbsp;million in the quarter. Capex was&nbsp;$3.2&nbsp;million due to aircraft maintenance and purchase of aircraft in the Medical Segment.
Free Cash Flow before aircraft acquisitions improved by&nbsp;$14.0&nbsp;million&nbsp;to&nbsp;$(2.7)&nbsp;million in the quarter.
Rob Wiesenthal, Blade&#8217;s chief executive officer, said, &#8220;Our strong Passenger Segment results reflect several factors including our durable competitive positioning along with the important actions we&#8217;ve taken recently to improve profitability such as our exit from Canada and broad-based cost rationalization initiatives.&#8221;
Will Heyburn, chief financial officer added, &#8220;Our Medical business is well positioned to prosper in the current environment given the strength of our logistics platform, strong underlying transplant volume growth, limited economic sensitivity and insulation from tariffs.&#8221;
2025&nbsp;Outlook:&nbsp;Blade Air Mobility expects revenue of&nbsp;$245 million&nbsp;–&nbsp;$265 million&nbsp;versus consensus of&nbsp;$256.3 million&nbsp;and <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44301933/blade-air-mobility-soars-as-q4-revenue-beats-expectations-and-medical-segment-shines" rel="noreferrer noopener">double-digit Adjusted EBITDA.</a>
Heyburn added, &#8220;We continue to expect improving results throughout the rest of the year in both business lines. In Medical, we are onboarding additional new customers and expect continued growth with existing customers. In Passenger, while the economic outlook may be uncertain, we still expect ongoing year-over-year benefits from cost and restructuring actions, as we will not anniversary our implementation of most items <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">until the fourth quarter of this year.</a>&#8220;
Melissa Tomkiel, president, stated, &#8220;Following a period of unusually heavy scheduled aircraft maintenance and associated downtime during the first half of 2025, we expect a significant improvement in the second half of the year through 2026, resulting in reduced capital expenditures and improved Medical Segment Adjusted EBITDA margins.&#8221;
Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).
Price Action: BLDE shares are up 14.7% at $3.35 at the last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/02/43781179/joby-vs-archer-vs-blade-which-evtol-stock-is-ready-for-takeoff" target="_blank" rel="noreferrer noopener">Joby Vs. Archer Vs. Blade: Which eVTOL Stock Is Ready For Takeoff?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Guidance

Small Cap

Movers

ARKX

BLDE

Blade Beats Q1 Forecasts As Jet Surge, Short Flights Drive Gains

Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Eton Pharmaceuticals to report an earnings per share (EPS) of $0.03.
The announcement from Eton Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 1.36% increase in the share price on the following day.
Here's a look at Eton Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>0.02</td>
<td>-0.12</td>
<td>-0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>16.0%</td>
<td>3.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058590_0.png" alt="eps graph" />
<h3>Performance of Eton Pharmaceuticals Shares</h3>
Shares of Eton Pharmaceuticals were trading at $16.79 as of May 09. Over the last 52-week period, shares are up 360.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Eton Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Eton Pharmaceuticals.
The consensus rating for Eton Pharmaceuticals is Buy, derived from 3 analyst ratings. An average one-year price target of $27.67 implies a potential 64.8% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 94.04% downside.</li>
<li>Analysts currently favor an Buy trajectory for Zevra Therapeutics, with an average 1-year price target of $22.0, suggesting a potential 31.03% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $27.33, suggesting a potential 62.78% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eton Pharmaceuticals</td>
<td>Buy</td>
<td>59.26%</td>
<td>$6.48M</td>
<td>-2.96%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>-1.36%</td>
<td>$52.01M</td>
<td>-25.45%</td>
</tr>
<tr>
<td>Zevra Therapeutics</td>
<td>Buy</td>
<td>-6.79%</td>
<td>$10.68M</td>
<td>-65.31%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>-17.39%</td>
<td>$10.77M</td>
<td>-14.91%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Eton Pharmaceuticals ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>Unveiling the Story Behind Eton Pharmaceuticals</h3>
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
<h3>Unraveling the Financial Story of Eton Pharmaceuticals</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Eton Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 59.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Eton Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Eton Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.96% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Eton Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -1.07%. This signifies efficient management of assets and strong financial health.
Debt Management: Eton Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 1.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ETON/earnings">To track all earnings releases for Eton Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETON

A Look Ahead: Eton Pharmaceuticals's Earnings Forecast

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Herbalife to report an earnings per share (EPS) of $0.41.
The market awaits Herbalife's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.14 in the last quarter, leading to a 42.7% increase in the share price on the following day.
Here's a look at Herbalife's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.22</td>
<td>0.35</td>
<td>0.41</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.59</td>
<td>0.36</td>
<td>0.57</td>
<td>0.54</td>
<td>0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>43.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058577_0.png" alt="eps graph" />
<h3>Tracking Herbalife's Stock Performance</h3>
Shares of Herbalife were trading at $6.73 as of May 09. Over the last 52-week period, shares are down 36.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HLF/earnings">To track all earnings releases for Herbalife visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Herbalife's Earnings Forecast

Press Releases

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Health Care

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Biomea Fusion

Citius Oncology

Cue Biopharma

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

Immix Biopharma

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MAIA Biotechnology

Seres Therapeutics

Metagenomi

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Pyxis Oncology

Repare Therapeutics

Serina Therapeutics

Skye Bioscience

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Wells Fargo

Guggenheim

Morgan Stanley

HC Wainwright & Co.

카발레타 바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>)의 주가는 수요일 24.38% 상승한 3.01달러에 마감했으며, 전신 경화증(Systemic Sclerosis) 약물 시험 업데이트 이후 시간외 거래에서 4.65% 상승한 주당 3.15달러에 거래되었다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-668671" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28004158/CANA-SHares-1024x282.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28004158/CANA-SHares-1024x282.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28004158/CANA-SHares-300x83.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28004158/CANA-SHares-768x212.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28004158/CANA-SHares-1536x423.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/28004158/CANA-SHares.png 1746w" alt="" width="1024" height="282" /></figure>
또한 읽어보세요: <a href="https://www.benzinga.com/general/market-summary/24/11/42212364/trumps-tariff-threat-to-canada-may-disrupt-oil-markets-inflate-prices-would-likely-raise-the-price-of-fuels-says-analyst">트럼프의 캐나다 관세 위협은 석유 시장을 혼란스럽게 하고 가격을 인상할 수 있다: &#8216;연료 가격을 올릴 가능성이 높다&#8217;고 분석가가 말했다</a>
무슨 일이 있었나: 이 회사는 2025년에 미국 식품의약국(FDA)와 만나 등록 임상 시험 설계에 대해 논의할 예정이라고 델브인사이트 비지니스 리서치(DelveInsight Business Research)의 성명서를 통해 발표했다.
이 보고서에 따르면, 카발레타는 2024년 미국 류마티스학회 컨버전스에서 발표된 긍정적인 임상 안전성 및 효능 데이터를 선보였다. 이 전신 경화증 치료제 임상 시험은 16명의 환자를 대상으로 진행 중이며, 2024년 11월 12일 기준으로 10명의 환자가 용량을 투여받았다.
왜 중요한가: 이 주가는 수요일에 주당 3달러를 처음으로 넘어섰고, 11월 15일 이후 처음으로 상승했다. 또한, 이 주가가 단 하루에 24% 이상 상승한 것은 2022년 12월 14일 이후 2년 만에 처음이다.
카발레타 바이오는 자가면역 질환에 대한 지속적이고 잠재적으로 치유적인 치료법을 제공하기 위해 엔지니어링된 T세포 치료제를 개발하는 데 전념하고 있다. 그들의 CABA 플랫폼에는 키메라 항원 수용체 T세포와 독자적인 키메라 자가항체 수용체 T세포가 포함되어 있으며, 자가면역 질환을 표적화하도록 설계되었다.

이미지 출처: Unsplash
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42186167/michael-saylors-microstrategy-convertible-notes-to-buy-bitcoin-offer-no-interest-so-why-are-investors-rushing-to-buy-them">마이클 세일러의 마이크로스트레티지 전환사채가 비트코인을 사는데 이자를 제공하지 않는데, 왜 투자자들이 몰려드는 걸까요?</a></li>
</ul>
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Cabaletta Bio

뉴스

에 대한 최신 뉴스 Cabaletta Bio (NASDAQ:CABA) 주식

목요일, 11월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌